GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » Price-to-Owner-Earnings

Achieve Life Sciences (Achieve Life Sciences) Price-to-Owner-Earnings : (As of Apr. 30, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Achieve Life Sciences Price-to-Owner-Earnings?

As of today (2024-04-30), Achieve Life Sciences's share price is $4.40. Achieve Life Sciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Achieve Life Sciences's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Achieve Life Sciences was 73.23. The lowest was 0.01. And the median was 0.04.


ACHV's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.37
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-30), Achieve Life Sciences's share price is $4.40. Achieve Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.51. Therefore, Achieve Life Sciences's PE Ratio for today is At Loss.

As of today (2024-04-30), Achieve Life Sciences's share price is $4.40. Achieve Life Sciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.51. Therefore, Achieve Life Sciences's PE Ratio without NRI for today is At Loss.


Achieve Life Sciences Price-to-Owner-Earnings Historical Data

The historical data trend for Achieve Life Sciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences Price-to-Owner-Earnings Chart

Achieve Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Achieve Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Achieve Life Sciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Achieve Life Sciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achieve Life Sciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Price-to-Owner-Earnings falls into.



Achieve Life Sciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Achieve Life Sciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.40/-1.44
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achieve Life Sciences  (NAS:ACHV) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Achieve Life Sciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Achieve Life Sciences (Achieve Life Sciences) Business Description

Traded in Other Exchanges
Address
22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.
Executives
John Bencich officer: CFO and PFO 2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Sellig director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Braxton King director 91 JAMES AVENUE, ATHERTON CA 94027
Dialectic Life Sciences Spv Llc 10 percent owner C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Ls Manager Llc 10 percent owner 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
John Fichthorn 10 percent owner C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004
Dialectic Capital Management, Lp 10 percent owner 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Partners, Llc 10 percent owner 2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Financial Group Svb 10 percent owner 2270 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii, Llc 10 percent owner 2770 SAND HILL ROAD, MENLO CITY CA 94025
Svb Innovation Credit Fund Viii, L.p. 10 percent owner C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025
Innovation Credit Fund Viii-a, L.p. 10 percent owner 2770 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii-a, Llc 10 percent owner 2770 SAND HILL ROAD, MENLO CITY CA 94025